Puma Biotechnology, Inc. (PBYI): EBITDA
$48.24M
Year ended 2025-12-31
$40.91M
Trailing 12 months to 2026-06-30
+12.9%
3-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.24M | +13.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $42.49M | -3.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $44.16M | +31.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $33.56M | +166.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $12.60M | n/c | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$20.37M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$30.97M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$87.27M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$289.58M | n/m | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | -$275.45M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$239.50M | n/m | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | -$141.65M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$54.41M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$74.19M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$10.15M | n/a | 2014-03-03, From 2011-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $48.24M | +13.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $48.45M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$156.61M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$376.00M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$160.87M | n/m |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$115.50M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $74.78M | +491.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $15.06M | -6.5% |
| Harrow, Inc. (HROW) | 2025-12-31 | $32.43M | +203.9% |
Compare PBYI, ANAB, IDYA, RCUS side by side · Screen every company in Pharmaceutical Preparations ↗